Antonio Liras Martin

Prof. Dr. Antonio Liras Martin


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JMJuan Andrés De Pablo Moreno
Juan Andrés De Pablo Moreno
ABAndrea Miguel Batuecas
Andrea Miguel Batuecas
MSMaría de Sancha
María de Sancha
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.

6 October 2023 in Thrombosis Research
Verified
Journal Article
Open access
JPJuan A. De Pablo-Moreno
Juan A. De Pablo-Moreno
AMAndrea Miguel-Batuecas
Andrea Miguel-Batuecas
ERE. Carlos Rodríguez-Merchán
E. Carlos Rodríguez-Merchán
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
Congenital coagulopathies have, throughout the history of medicine, been a focus of scientific study and of great interest as they constitute an alteration of one of the most important and conserved pathways of evolution. The first therapeutic strategies developed to address them were aimed at restoring the blood components lost during hemorrhage by administering whole blood or plasma. Later on, the use of cryoprecipitates was a significant breakthrough as it made it possible to decrease the volumes of blood infused. In the 1970' and 80', clotting factor concentrates became the treatment and, from the 1990's to the present day, recombinant factors -with increasingly longer half-lives- have taken over as the treatment of choice for certain coagulopathies in a seamless yet momentous transition from biological to biotechnological drugs. The beginning of this century, however, saw the emergence of new advanced (gene and cell) treatments, which are currently transforming the therapeutic landscape. The possibility to use cells and viruses as well as specific or bispecific antibodies as medicines is likely to spark a revolution in the world of pharmacology where therapies will be individualized and have long-term effects. Specifically, attention is nowadays focused on the development of gene editing strategies, chiefly those based on CRISPR/Cas technology. Rare coagulopathies such as hemophilia A and B, or even ultra-rare ones such as factor V deficiency, could be among those deriving the greatest benefit from these new developments.

2 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJuan Andrés De Pablo Moreno
Juan Andrés De Pablo Moreno
LGLeopoldo González-Brusi
Leopoldo González-Brusi
ABAndrea Miguel Batuecas
Andrea Miguel Batuecas
PBPablo Bermejo-Álvarez
Pablo Bermejo-Álvarez
LRLuis Revuelta
Luis Revuelta
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
Factor V deficiency is a congenital coagulation disorder characterized by the absence or malfunction of factor V (FV). The purpose of this study was to develop a viable FV-deficient mouse model using CRISPR/Cas9 technology. A viable pathological model of the disease was not available to develop new therapies. A previous in silico study was performed to select a mutation causing a mild disease phenotype in humans (Thr1898Met missense). Such mutation was replicated in mice by CRISPR-mediated homology directed repair. Following crossing, homozygous individuals were subjected to coagulometry assays, including FV levels, prothrombin time (PT), and activated partial thromboplastin time (aPTT). The in silico study suggested that the mutation destabilizes FV structure of both mouse and human variants, putatively producing a mild phenotype of the disease in mice. Mendelian inheritance was observed in the offspring. No spontaneous signs of blood clotting disturbances, premature deaths or gestational dysfunctions were observed. FV levels in homozygous animals were 24.5% ± 5.1; 39.7 sec ± 2.8; PT was 61.8% ± 6.3; 23.4 sec ± 1.6 (INR = 1.47 ± 0.12); and aPTT was 46.9 sec ± 3.2. A viable FV-deficient mouse model was generated by introducing a missense mutation in FV. The model exhibits a mild phenotype of the disease, akin to that observed in humans.

12 February 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAndrea Miguel-Batuecas
Andrea Miguel-Batuecas
JPJuan A. De Pablo-Moreno
Juan A. De Pablo-Moreno
NPNéstor Porras
Néstor Porras
PBPablo Bermejo-Álvarez
Pablo Bermejo-Álvarez
LGLeopoldo González-Brusi
Leopoldo González-Brusi
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
Factor V is an essential protein in the blood clotting process and plays a central role in secondary hemostasis. Its deficiency causes a rare inherited disorder characterized by episodes of severe bleeding, some of which can be life-threatening. Although previous studies have established that factor V is essential for normal embryonic development, its specific contribution to vascular maturation remains incompletely understood, factor V is believed to contribute to blood vessel stabilization and regulate angiogenesis through its interaction with thrombin. In a recent study, a CRISPR-engineered mouse model intended to produced a mild factor V deficiency disease, unexpectedly produced a frameshift mutation in the A3 domain, resulting in a truncated protein. Factor V levels in healthy embryonic mouse tissues were assessed to investigate its role at different developmental stages. The mutation markedly impaired viability, as homozygous mice exhibited a lethal phenotype with severe bleeding and perinatal death, along with impaired coagulation function. Histopathological and immunohistochemical analyses indicated a link between factor V deficiency, thrombin and α-smooth muscle actin, potentially affecting proangiogenic signaling and embryonic vascular formation. Factor V gene expression increased during late embryogenesis, underscoring its importance in vascular development and maturation. Overall, these findings are consistent with a role for factor V in stabilizing embryonic blood vessels and modulating thrombin-dependent angiogenesis, and add further detail on the developmental impact of its deficiency and the pathogenesis of congenital bleeding disorders.

1 October 2024 in Anales de la Real Academia Nacional de Farmacia
Verified
Journal Article
Closed access
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
In the history of societies, in general, there is a progressive evolution, which runs parallel to the progress of science and, in particular, of Medicine. Perhaps it is necessary to consider, without fear of misunderstanding, that Pharmacology has allowed us to live longer and better. If we look back, especially those of us who have had the good fortune of having a very old apothecary’s shop, where perhaps our great-grandfather was a pharmacist, a lifelong pharmacist, in an almost lost village in the former Castilla La Vieja, around the second half of the 19th century, we can better appreciate the progress that has been made. But, in addition, if the great-grandson in question chose to follow a family tradition of being an apothecary, things take on a different dimension, especially when his vocation has been of university professor in Pharmacy and of researcher in Biotechnology. Knowing that we are facing an extraordinarily novel pharmacological reality, it would seem that we are moving in the world of magic and surprise. Because the therapeutic purposes that are being pursued at the present time were unimaginable decades ago, and even less so with the current techniques, pharmaceutical forms and procedures that are a combination of the multidisciplinary activity of many specialists. In this evolution that goes from magistral formulas, of empirical utility, to new advanced therapies, areas have been born that are the combination of different knowledge, such as Pharmacobiotechnology. We also control, in part, biology in its most intimate “soul”, which is the genome, and we are able to create animal models with a specific pathology to study new drugs. Pharmacobiotechnology has made it possible to obtain recombinant therapeutic proteins in the laboratory; recombinant mono- and bispecific antibodies for the treatment of cancer and other diseases and, through new therapies, gene therapy and cell therapy, it is possible to correct alterations in the genes that give rise to many hereditary diseases. However, in this new world of modern pharmacology, which will be largely individualized, the bioethics of healing must be kept in mind, lest the new high-cost procedures can further increase social inequity. Keywords: Advances in Biomedicine; History; Biotechnology; Advanced therapies; Rare diseases

31 March 2025 in Anales de la Real Academia Nacional de Farmacia
Verified
Journal Article
Closed access
Antonio Liras MartinAntonio Liras Martin
Antonio Liras Martin
SBSara Bernal
Sara Bernal
PBPablo Bermejo-Álvarez
Pablo Bermejo-Álvarez
LSLuis J. Serrano
Luis J. Serrano
ABAndrea Miguel- Batuecas
Andrea Miguel- Batuecas
LRLuis Revuelta
Luis Revuelta
This work represents a retrospective and updated review in a scientific context of itself, the Advanced Therapies group of the Complutense University of Madrid. The project, which began almost 7 years ago, has pursued the establishment of gene and cell therapy protocols for the treatment of coagulation factor V deficiency. This “trip” has been possible thanks to the Association for the Research and Cure of Factor V Deficiency, A Hope for Celia, through micro sponsorship or crowdfunding and through predoctoral contracts granted by the Complutense University of Madrid. The results obtained and presented in the present work have been very successful for this ultra-rare disease. The project was initiated with the complete study of the mutational cause in a patient (Celia) and the study of her progenitor segregation; then, with the establishment of cellular and live animal models for the pathological mutation, using gene editing with CRISPR, the measurement of factor V in mice was standardized, and finally, the proof of concept of a gene therapy lentiviral protocol was demonstrated. All these results have given rise to several articles published in high-impact journals and two that are in the process of editorial review. Two patents have also been obtained on the correction of mutations in the F5 gene by gene editing and another on the viable animal model itself with factor V deficiency. All these results open the door to future approaches in the preclinical phase in animal models to establish the guarantees of efficacy and safety of the gene therapy protocol with lentiviral vectors. Keywords: Hemostasis and factor V deficiency; rare diseases; cellular and animal models of pathology; advanced therapies; gene therapy; CRISPR gene editing